Targetting VEGFR is an important strategy in combatting tumour growth and metastatic spread. VEGFR stimulates new blood vessel formation to the tumour and allows blood supply to reach metastatic growths. By blocking VEGFR either directly by using a VEGFR inhibitor or indirectly by inhibiting a down stream signalling pathway such as the PI3 Kinase / Akt pathway. In this way a PI3K inhibitor or an Akt inhibitor can be used to block VEGFR mediated signalling. The PI3K / Akt pathway is also involved in the drug resistance mechanism for Zytiga. An inhibitor of PI3K or Akt would stop resistance to Zytiga and greatly prolong its duration of action.
PI3K / Akt pathway inhibitors under investigation in combination with Zytiga and Prednisone.
1. Salvestrol Zytiga Combo. Includes the PI3K inhibitor salvestrol Q40.
2. GDC-0980 Zytiga Combo. PI3K reversible inhibitor.
3. PX-866 Zytiga Combo. PI3K irreversible inhibitor.
4. GDC-0068 Zytiga Combo. Akt reversible inhibitor.
VEGFR Inhibitors in combination with Zytiga will help stop the spread of the cancer and reduce bone mets.
VEGFR Inhibitors under investigation in combination with Zytiga and Prednisone.
1. Cabozantinib Zytiga Combo.
2. Sunitinib Zytiga Combo.
No comments:
Post a Comment